Partnership20 Oct 2024, 06:34 pm
Rossari Biotech Reports Q2 FY25 Revenue Growth of 3.1% YoY, EBITDA Up 3.6%, and PAT Up 7.3%
AI Summary
Rossari Biotech Limited, a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions, has announced its financial results for the quarter ended September 30, 2024. The company reported a 3.1% YoY increase in revenue from operations, a 3.6% improvement in EBITDA, and a 7.3% increase in PAT. The Textile business is navigating headwinds, but a recovery is expected in the next calendar year. Exports grew by 32% in H1 FY25, providing support to overall performance amidst softer domestic growth. The company is committed to innovation and customer-centric solutions, and is working towards expanding its global footprint.
Key Highlights
- Revenue from operations grew 3.1% to Rs. 498.4 crore as compared to Rs. 483.5 crore
- EBITDA improved by 3.6% to Rs. 65.9 crore from Rs. 63.6 crore
- PAT increased by 7.3% to Rs. 35.3 crore from Rs. 32.9 crore
- Exports grew by 32% in H1 FY25
- Company is expanding its global footprint through its own manufacturing set up and sales & distribution network overseas